Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when VKTX files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsViking Therapeutics holds routine 2026 Annual Meeting, elects two directors
Filed May 26, 2026 · Period ending May 19, 2026 · ~1 min read
Key Changes
-
low
Shareholders elected J. Matthew Singleton and S. Kathryn Rouan as Class II directors for three-year terms through 2029. Quorum of 69.1% of outstanding shares represented at virtual meeting.
Item 5.07 verify on EDGAR → -
low
Stockholders ratified CBIZ CPAs P.C. as independent auditor for fiscal 2026 with 98% approval (78.4M votes for vs 1.2M against).
Item 5.07 verify on EDGAR → -
low
Executive compensation received shareholder approval in advisory vote, consistent with standard annual meeting procedures.
Item 5.07 verify on EDGAR →
Summary
Viking Therapeutics filed a routine 8-K disclosing results from its May 19, 2026 Annual Meeting of Stockholders. The meeting covered standard corporate governance matters with no surprises: two directors were re-elected to three-year terms, the audit firm was ratified, and executive pay was approved. With nearly 70% of shares represented, the company met quorum requirements and all proposals passed.
For retail investors, this filing has no immediate investment implications. It's purely procedural—the kind of annual housekeeping every public company performs. The director elections maintain board continuity, and the auditor ratification (CBIZ CPAs) ensures financial reporting oversight continues unchanged. Watch for Viking's next quarterly earnings report or pipeline updates for material business developments. Annual meeting votes like these rarely move the stock unless there's unexpected opposition or governance controversy, neither of which occurred here.
Section-by-Section Diff
Event · Item 5.07 — Submission of Matters to a Vote of Security Holders
Viking Therapeutics held its 2026 Annual Meeting, electing two Class II directors and ratifying auditor selection and executive compensation.
Show 3 minor / wording changes
Added in current filing · verify on EDGAR →
On May 19, 2026, Viking Therapeutics, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”). Of the 115,893,943 shares of the Company’s common stock outstanding as of March 20, 2026, the record date for the Annual Meeting, 80,089,532 shares were represented at the Annual Meeting virtually or by proxy, constituting approximately 69.1% of the outstanding shares entitled to vote and constituting a quorum for the transaction of business.
The company held its annual shareholder meeting on May 19, 2026, with 69.1% of outstanding shares represented, meeting quorum requirements. Three proposals were voted on: director elections, auditor ratification, and executive compensation approval.
Added in current filing · verify on EDGAR →
As a result, the Company’s stockholders voted to elect J. Matthew Singleton and S. Kathryn Rouan, Ph.D., as Class II directors to serve until the Company’s 2029 annual meeting of stockholders or until such director’s respective successor is duly elected and qualified.
Shareholders elected J. Matthew Singleton and S. Kathryn Rouan, Ph.D., as Class II directors to serve three-year terms until 2029. Singleton received 28,648,459 votes for versus 14,562,012 withheld, while Rouan received 21,960,203 for versus 21,250,268 withheld.
Added in current filing · verify on EDGAR →
As a result, the Company’s stockholders voted to ratify the selection of CBIZ CPAs P.C. as the Company’s independent registered public accounting firm for its fiscal year ending December 31, 2026.
Shareholders ratified CBIZ CPAs P.C. as the company's independent auditor for fiscal year 2026 with 78,368,957 votes for, 1,241,969 against, and 478,606 abstentions. This is a routine annual approval of the audit firm.
Event · Item 9.01 — Financial Statements and Exhibits
Viking Therapeutics filed a procedural 8-K with only an interactive data file exhibit; no material business events disclosed.
Show 1 minor / wording change
Added in current filing · verify on EDGAR →
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. | Exhibit No | Description | 104 Cover Page Interactive Data File, formatted in Inline Extensible Business Reporting Language (iXBRL).
This 8-K contains only a routine exhibit filing (interactive data file in iXBRL format) with no substantive business disclosures. The filing appears to be a technical or procedural submission required for SEC compliance.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · May 27, 2026 · How we verify